In the Literature: On Clinical Performance Measures and Outcomes Among Hemodialysis Patients

American Journal of Kidney Diseases

Volumn 49, Issue 3, 2007, Pages 352-355

  Parfrey, Patrick S ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; MEASUREMENT; MORTALITY; OUTCOME ASSESSMENT; PERFORMANCE; SURVIVAL RATE;

BIOLOGICAL MARKERS; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33847309142     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.01.019     Document Type: Editorial

References (16)

1. U.S. Renal Data System. 2003 USRDS Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2003), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. Rocco M.V., Frankenfield D.L., Hopson S.D., and McClellan W.M. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med 14 (2006) 512-519
3. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 7 (1996) 728-736
4. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28 (1996) 53-61
5. Collins A.J. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int (Suppl) 80 (2002) 44-48
6. Port F.K., Ashby V.B., Dhingra R.K., Roys E., and Wolfe R.A. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13 (2002) 1061-1066
7. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
8. Parfrey P.S., Foley R.N., Wittreich B.H., Sullivan D.J., Zagari M.J., and Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005) 2180-2189
9. Drüeke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
10. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
11. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance dialysis. N Eng J Med 347 (2002) 2010-2019
12. Greene T., Daugirdas J., Depner T., et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose targeting in bias". J Am Soc Nephrol 16 (2005) 3371-3380
13. Lowrie E.G., Laird N.M., Parker T.F., and Sargent J.A. Effect of the hemodialysis prescription on patient morbidity: report from the National Co-operative Dialysis Study. N Eng J Med 305 (1981) 1176-1181
14. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. BMJ 300 (1990) 573-578
15. Woods J.D., Turenne M.N., Strawderman R.L., et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis 30 (1997) 50-57
16. Hodgkinson K.A., Parfrey P.S., Bassett A.S., et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cariomyopathy (ARVD5). J Am Coll Cardiol 45 (2005) 400-408